This clinical trial is focused on studying the effects of a medication called Otezla, which contains the active ingredient apremilast. The study is designed to evaluate the safety and effectiveness of this medication in treating a rare skin condition known as epidermolysis bullosa simplex (EBS). EBS is a genetic disorder that causes the skin to be very fragile, leading to the formation of blisters from minor injuries or friction. The trial will involve patients who are 6 years of age or older and have a confirmed diagnosis of a severe form of EBS due to specific genetic mutations.

The purpose of the study is to assess how well apremilast works in reducing the symptoms of EBS, such as the number of new blisters, and to evaluate its safety for patients. The study will follow a specific design where patients will receive the medication in different phases to observe its effects. Participants will take Otezla in the form of film-coated tablets, which are taken orally. The maximum daily dose is 60 milligrams, and the treatment period can last up to 16 weeks. During the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the trial, researchers will monitor various aspects of the patients’ health, including the severity of their condition, any itching or pain they experience, and their overall quality of life. The study also aims to validate a new scale for measuring the severity of EBS. By the end of the trial, the researchers hope to gather valuable information on the potential benefits and risks of using apremilast for treating EBS, which could lead to improved treatment options for those affected by this challenging condition.